News

Zydus Lifesciences has received a Warning Letter from the United States Food and Drug Administration (USFDA) relating to its formula on manufacturing facility located at Baddi, Himachal Pradesh. The Warning Letter was issued in response to a request for records pursuant to sec on 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any onsite inspection of the facility by the USFDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. The company added that the said Warning Letter will not impact current operations and supplies from the Baddi site. The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspec on, the Company received the Establishment Inspection Report (EIR) in October 2025, with the final compliance status classified as Voluntary Ac on Indicated (VAI).

Zydus Lifesciences and its various subsidiaries has invested balance 9.01 crore for subscription of 90,17,848 equity shares under Tranche 2, 3 and 4 of Torrent Urja 25, representing 22.06% of its paid-up share capital. Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026. In June 2025 under Tranche 1, the company and its subsidiaries had invested Rs 3.86 crore for subscription of 38,64,792 equity shares of Torrent Urja 25, representing 22.06% of its paid-up share capital.

Zydus Lifesciences announced that the Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Zydus Lifesciences announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Zydus Lifesciences rose 8.68% to Rs 1272.50 crore in the quarter ended March 2026 as against Rs 1170.90 crore during the previous quarter ended March 2025. Sales rose 18.19% to Rs 7434.40 crore in the quarter ended March 2026 as against Rs 6290.20 crore during the previous quarter ended March 2025.For the full year,net profit rose 11.37% to Rs 5040.00 crore in the year ended March 2026 as against Rs 4525.50 crore during the previous year ended March 2025. Sales rose 18.37% to Rs 26719.70 crore in the year ended March 2026 as against Rs 22573.80 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7434.406290.20 18 26719.7022573.80 18 OPM %34.3633.79 -31.7231.27 - PBDT2565.602129.50 20 8545.707162.10 19 PBT2057.201891.60 9 7137.706246.30 14 NP1272.501170.90 9 5040.004525.50 11 Powered by Capital Market - Live News